Exporting, as a cornerstone of sustainable growth and a symbol of industrial maturity, plays a vital role in enhancing national competitiveness and expanding Iran’s presence in global markets. The export of knowledge-based products, such as those developed by AryoGen Pharmed, reflects the scientific and industrial capabilities of the country at an international level and serves as a key driver of sustainable economic growth. Companies active in this field, by leveraging advanced technologies and maintaining competitive quality standards, contribute significantly to foreign exchange earnings and the expansion of Iran’s export markets.

At the National Export Day ceremony, held on Tuesday, October 21, 2025, AryoGen Pharmed, which had been recognized as a National Model Exporter for the past five consecutive years, once again stood out. Demonstrating excellence in areas such as consistent national recognition, the highest evaluation scores, advanced production technologies, and a strong global brand reputation, AryoGen Pharmed earned the distinguished title of “The Nation’s Top Exporter.” This achievement reaffirms AryoGen Pharmed’s unwavering commitment to sustainable development, scientific innovation, and a strong presence in international markets.
Mr. Mohammad Safarioun, CEO of AryoGen Pharmed, highlighted the company’s achievements in his speech at the ceremony, stating:
“AryoGen Pharmed, as the largest exporter of biopharmaceutical products in Iran, has succeeded in achieving a positive trade balance for the first time — where the value of its exports and foreign exchange earnings exceeds its imports and foreign currency expenditures. The company has also helped eliminate concerns about the shortage of advanced biotechnological medicines for patients and the healthcare system.
The CinnaGen Pharmaceutical Group, with the production of 100 types of medicines for patients with hard-to-treat diseases, stands as the largest producer of biological medicines in Iran and has saved the country 4.5 billion dollars in foreign currency.
Mr. President, consider that the national pharmaceutical import budget is 4 billion dollars — and without companies like the CinnaGen Group, no budget would remain for medicines. I must emphasize this point again: if the production of these 100 medicines did not exist domestically, there would be no budget available for importing such critical drugs for patients with severe illnesses.”
The continued success of AryoGen Pharmed in the production and export of biopharmaceuticals stands as a testament to Iran’s scientific and industrial capabilities and represents a significant stride toward the nation’s sustainable economic growth.
We proudly extend our heartfelt congratulations to every member of the AryoGen Pharmed family for this national achievement.